Cardiocore announced the launch of its redesigned corporate Web site that provides users with a comprehensive view of Cardiocore's history as a top-quality, innovative core lab.
Site Highlights Core Lab’s Leadership in Service, Science and Data Management
Washington, DC—Cardiocore, a premier centralized cardiac testing lab, announced the launch of its redesigned corporate web site at http://www.cardiocore.com. The company’s new Internet presence provides users with a comprehensive view of Cardiocore’s history as a top-quality, innovative core lab.
“The new site delivers insights to Cardiocore’s leadership in global service, expert science and advanced data management,” said Cardiocore Vice President of Sales, Robert Goodman. He continued, “Visitors may easily find useful information about Cardiocore’s offerings such as ECG, Holter, ECHO and MUGA analyses, as well as protocol development, scientific reporting and statistics.”
Founded by a cardiac research expert and led by a clinical data management veteran, Cardiocore is often recognized as an innovator in the application of cardiac data technology. Focusing on that differentiator, Cardiocore Vice President of Marketing, Scott Satin noted, “The new site offers details about sponsor-benefiting technologies such as CardioPortal™—the company’s advanced web-based data delivery service, and HolterGateway™—Cardiocore’s leading-edge Holter data transfer system.” He added, “The new home page includes a link for direct login to CardioPortal by customers and clinical site personnel around the world.”
The newly launched web site also provides sponsors and investigators rapid access to experienced professionals located at Cardiocore’s three office locations. The company’s global headquarters is located outside Washington, DC, its US West Coast operation is in San Francisco, CA, and its European operation is based in London, UK.
About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 16 years. Services include centralized electrocardiography (ECG), Holter, echocardiography (ECHO), multigated acquisition scans (MUGA), and consulting services such as protocol development, scientific reporting and statistical analyses. The company is experienced in the design and the implementation of cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company’s advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.